Sapala Organics

What Sapala Organics does

Sapala Organics is a Hyderabad, India-based contract research, development, and manufacturing organization (CRO/CDMO) that specializes in nucleic acid chemistry and medicinal chemistry for drug discovery and life sciences. The company synthesizes modified nucleosides, phosphoramidites, and specialized building blocks — including sugar-modified chemistries (LNAs, BNAs, morpholino, 4'-thio, acyclic and pyranose nucleosides), base-modified nucleosides, backbone-modified oligonucleotides (PS, PdiS, diastereopure amidites), GalNAc conjugates for hepatocyte-targeted delivery, carbohydrate building blocks, and fluorescent dyes — and supplies mRNA raw materials such as pseudouridine, N1-methyl pseudouridine, and dinucleotide/trinucleotide caps at multi-kilogram scale. It also offers custom chiral synthesis across four asymmetric methodologies and is described as India's only CDMO focused exclusively on nucleic acid chemistry.

The company serves pharmaceutical companies, biotech firms, academic institutions, oligonucleotide CDMOs, therapeutic developers of RNA-based and antisense therapies, mRNA vaccine innovators, and sequencing technology providers across six target verticals. Engagement is delivered through three models — CRO/FTE (embedded dedicated scientists), CDMO/FFS (project-based custom synthesis and cGMP manufacturing), and Analytical Services (NMR, LC-MS, HPLC, GC, thermal, wet analysis) — supplemented by a catalog of manufactured products (SNP nucleoside and phosphoramidites derivatives, SLS linkers and spacers, SPEG PEG derivatives). Sapala operates 18 R&D labs, employs 250+ people including 20+ PhDs, and maintains offices in Hyderabad, two locations in Japan, and two US locations (Encinitas, CA and Monmouth Junction, NJ).

Sapala Organics is a wholly-owned subsidiary of Cohance Lifesciences Limited (formerly Suven Pharma Ltd) following a 2023 acquisition, with a further strategic partnership announced with Suven Pharmaceuticals in September 2024. Advent International maintains board influence through Cohance. The company holds ISO 9001:2015, ISO 27001:2013, and ISO 27701:2019 certifications, DSIR In-house R&D Unit recognition, and Drugs Control Administration Telangana approval.

Name

Sapala Organics

Legal name

Sapala Organics Pvt. Ltd.

Website

https://sapalaorganics.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Sapala Organics is an India-based CRO/CDMO specializing in nucleic acid chemistry and medicinal chemistry, manufacturing modified nucleosides, phosphoramidites, GalNAc conjugates, and mRNA raw materials for global pharma, biotech, academia, and mRNA vaccine developers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO/CRO)

NAICS

Medicinal and Botanical Manufacturing (325411), Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing (325194), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Industrial Organic Chemicals (2860), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Nucleic acid chemistry
• Medicinal chemistry services
• Contract development manufacturing
• Phosphoramidite synthesis
• Oligonucleotide building blocks

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. CRO Services (FTE Model): Full Time Equivalent service model offering clients direct access to dedicated scientists integrated into their research projects. Ideal for long-term collaborative partnerships with expertise in gram-scale to kilogram-scale synthesis.
2. CDMO Services (FFS Model): Fee For Service model providing tailored solutions for specific research assignments on a project basis. Includes process development, scale-up, and cGMP manufacturing.
3. Analytical Services: State-of-the-art analytical facility offering orthogonal analytical techniques for customers from early R&D to Pharma innovators. Services include spectroscopy, chromatography, spectrometry, thermal studies, and wet analysis.
4. Product Sales: Sale of chemical products including nucleoside and phosphoramidites derivatives, linkers and spacers, PEG derivatives, and miscellaneous products for oligonucleotide synthesis and drug discovery.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sapala Organics is a CRO/CDMO that researches, develops, and manufactures specialized synthetic organic compounds for the nucleic acid chemistry and medicinal chemistry value chains. It supplies custom-synthesized building blocks, modified nucleosides, phosphoramidites, linkers, PEG derivatives, and drug delivery compounds (including GalNAc conjugates), and delivers process development, scale-up, and analytical services to pharma, biotech, and academic customers worldwide.

Product overview

Sapala Organics is a CRO/CDMO (Contract Research Organization/Contract Development and Manufacturing Organization) specializing in nucleic acid chemistry and medicinal chemistry. The company offers a portfolio of chemical synthesis services organized around core chemistry disciplines including Nucleic Acid Chemistry, Medicinal Chemistry, Carbohydrate Chemistry, Lipid and GalNAc Chemistry, and Fluorescent Chemistry. Service delivery models include CRO services via Full Time Equivalent (FTE) staffing, CDMO services via Fee For Service (FFS) project-based work, and Analytical Services. Complementing the service offerings, Sapala manufactures and sells a catalog of chemical products including Nucleoside and Phosphoramidites Derivatives (SNP series), Linkers and Spacers (SLS series), and PEG Derivatives (SPEG series) used as building blocks and reagents for oligonucleotide synthesis and drug delivery applications.

Differentiator

Problem solved

Functional benefit

Brands

• Sapala R&D: R&D operations division of Sapala Organics
• Sapala Co. Ltd.

Quantifiable outcome

• Scale-up capability demonstrated: 500 grams (2007) to 26 kilograms (2022) of highly complex Amidites
• +2 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• Suven PharmaceuticalscoreStrategic or Co-development Partner · 17 September 2024A strategic partnership with Suven Pharmaceuticals expands Sapala's reach and strengthens their ability to deliver complex solutions at scale. This partnership enhances delivery capabilities for pharmaceutical manufacturing services.
• Cohance Lifesciences LimitedcoreStrategic or Co-development PartnerSapala Organics is now a proud subsidiary of Cohance Lifesciences Limited, a Global Pharma CDMO and specialty chemical innovator. This acquisition enables Cohance to leverage Sapala's expertise in the high-growth oligonucleotide and Nucleic Acid building blocks sector. The partnership unlocks manufacturing scale-up and global commercialization capabilities, enhancing Sapala's growth and elevating its pharmaceutical offerings.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Agilent Technologies: Major life sciences tools vendor including nucleic acid chemistry reagents and custom oligonucleotides. Comparable to Sapala's catalog product business (nucleosides, fluorescent dyes, amidites) but with a much broader and more diversified life sciences portfolio.
• Lonza: Global CDMO with established nucleic acid and oligonucleotide manufacturing services. Competes with Sapala for therapeutic oligo and mRNA customers, but operates globally and at significantly larger scale.
• Asymchem: Large China-based API and CDMO provider with growing oligonucleotide/nucleic acid chemistry capabilities. Comparable as a CDMO serving global pharma with similar scale ambitions, but materially larger and more diversified.
• WuXi AppTec: Global CRO/CDMO with oligonucleotide chemistry services among its broader portfolio. Overlaps Sapala's CDMO offering but operates at much greater scale and breadth, competing for similar therapeutic and mRNA customers.

Direct peers

• Nitto Denko Avecia: Oligonucleotide and nucleic acid therapeutics CDMO offering process development and cGMP manufacturing. Comparable to Sapala's CDMO-FFS engagement model, particularly for therapeutic oligo customers.
• TriLink BioTechnologies (Maravai LifeSciences): mRNA and oligonucleotide CDMO supplying NTPs, pseudouridine, CleanCap cap analogs, and modified nucleosides. Sapala's mRNA raw materials business (pseudouridine, N1-methyl pseudouridine, dinucleotide caps) is directly competitive with TriLink.
• ChemGenes: Specialty manufacturer of phosphoramidites, modified nucleosides, and oligonucleotide reagents. Directly comparable to Sapala's SNP series and nucleic acid building block catalog, serving the same oligo CDMO and therapeutic customers.
• Hongene Biotech: Asia-based CDMO focused on oligonucleotide and nucleic acid raw materials including phosphoramidites and modified nucleosides. Comparable to Sapala in geography (low-cost Asia), product scope (nucleic acid chemistry), and target customers (oligo CDMOs, therapeutic companies).
• Bio-Synthesis Inc. US-based CRO/CDMO specializing in custom oligonucleotide synthesis, modified nucleic acids, and phosphoramidites. Closely comparable to Sapala in product scope (modified nucleosides, custom oligo synthesis) and customer base (therapeutic and diagnostic companies).
• Glen Research: Supplier of phosphoramidites, modifiers, and reagents for oligonucleotide synthesis. Comparable to Sapala in serving therapeutic oligo developers with specialized amidites and linkers (Sapala's SLS series is a direct analog).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Sapala-Organics-Pvt-Ltd-322459974511068
• LinkedInlinkedin.com/company/sapala-organics-pvt-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sapala Organics